Optinose Expects XHANCE Net Revenues For FY24 To Be Between $85M-$95M; Sees Average XHANCE Net Revenue Per Prescription To Exceed $230 (Prior View: $220)
Portfolio Pulse from Benzinga Newsdesk
Optinose projects XHANCE net revenues for FY24 to be between $85M-$95M, with net revenue per prescription surpassing $230. Operating expenses are forecasted to be $95M-$101M, including $6M in stock-based compensation. The company anticipates positive GAAP income from operations for FY25.
May 14, 2024 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Optinose anticipates higher XHANCE net revenues for FY24 and expects positive income from operations by FY25, with operating expenses outlined for 2024.
The positive revenue forecast for XHANCE in FY24, coupled with the expectation of positive income from operations in FY25, suggests a strong financial outlook for Optinose. This could lead to increased investor confidence and potentially a rise in OPTN's stock price in the short term. The detailed operating expense forecast provides transparency, further supporting potential positive sentiment among investors.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100